Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis"

Abstract Number: 997 • 2012 ACR/ARHP Annual Meeting
Evidence of Novel Genetic Predictors of Methotrexate Efficacy in Rheumatoid Arthritis
Stella Aslibekyan¹, Maria I. Danila², Jin Sha¹, David T. Redden³, Richard J. Reynolds⁴, Elizabeth Brown⁵, Laura B. Hughes⁶, Molly S. Bray¹, Sarah L. Morgan⁷, Larry W. Moreland⁸, James R. O'Dell⁹, Jeffrey R. Curtis¹⁰, Robert P. Kimberly¹¹, Lindsey A. Criswell¹², Robert M. Plenge¹³, S. Louis Bridges Jr.¹⁴ and Donna K. Arnett¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Med/Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ³Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Univ of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, ⁶Med Div of Clin Imm & Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama Birmingham, Birmingham, AL, ⁸Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, ¹⁰Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, ¹¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹²Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ¹³Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹⁴Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX), a disease-modifying anti-rheumatic drug used as first-line therapy in rheumatoid arthritis (RA), is characterized by considerable heterogeneity in individual treatment response. We…
Abstract Number: 774 • 2012 ACR/ARHP Annual Meeting
A CD4+ T-Cell Gene Expression Signature Predicts Drug Survival On Methotrexate Monotherapy in Early Rheumatoid Arthritis
Arthur G. Pratt¹, Philip M. Brown², Simon J. Cockell³, Gillian Wilson⁴ and John D. Isaacs¹, ¹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom, ³Bioinformatics Unit, Newcastle University, Newcastle-upon-Tyne, United Kingdom, ⁴Directorate of Musculoskeletal Medicine, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom
Background/Purpose: The mechanism of action of methotrexate (MTX) in the management of rheumatoid arthritis (RA) remains incompletely understood. It is nonetheless capable of inducing clinical…
Abstract Number: 473 • 2012 ACR/ARHP Annual Meeting
The Addition of Another Disease-Modifying Anti-Rheumatic Drug to Methotrexate in Place of Infliximab Reduces the Flare Rate During 2 Years After Infliximab Discontinuation in Patients with Rheumatoid Arthritis
Hideto Kameda¹, Takahiko Kurasawa¹, Hayato Nagasawa², Koichi Amano³ and Tsutomu Takeuchi⁴, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Saitama Medical Ctr, Kawagoe, Japan, ³Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ⁴Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: The treatment strategy for rheumatoid arthritis (RA) should be divided into remission-induction phase and its maintenance phase. To date, the usefulness of the combination…
Abstract Number: 465 • 2012 ACR/ARHP Annual Meeting
The Comparative Effectiveness of Oral Methotrexate Versus Subcutaneous Methotrexate for the Treatment of Early Rheumatoid Arthritis
Glen S. Hazlewood¹, J. Carter Thorne², Janet E. Pope³, Gilles Boire⁴, Boulos Haraoui⁵, Carol A. Hitchon⁶, Edward Keystone⁷, Diane Tin⁸, CATCH Investigators⁹ and Vivian P. Bykerk¹⁰, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ⁴Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Toronto, ON, Canada, ¹⁰Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: To determine the comparative effectiveness of subcutaneous (sc) versus oral methotrexate (MTX) as initial therapy for patients with early rheumatoid arthritis (ERA) in routine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].